Literature DB >> 21712519

The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C.

Matthew S Freiberg1, Chung-Chou H Chang, Melissa Skanderson, Kathleen McGinnis, Lewis H Kuller, Kevin L Kraemer, David Rimland, Matthew B Goetz, Adeel A Butt, Maria C Rodriguez Barradas, Cynthia Gibert, David Leaf, Sheldon T Brown, Jeffrey Samet, Lewis Kazis, Kendall Bryant, Amy C Justice.   

Abstract

BACKGROUND: Whether hepatitis C virus (HCV) confers additional coronary heart disease (CHD) risk among human immunodeficiency virus (HIV) infected individuals is unclear. Without appropriate adjustment for antiretroviral therapy, CD4 count, and HIV-1 RNA and substantially different mortality rates among those with and without HIV and HCV infection, the association between HIV, HCV, and CHD may be obscured. METHODS AND
RESULTS: We analyzed data on 8579 participants (28% HIV+, 9% HIV+HCV+) from the Veterans Aging Cohort Study Virtual Cohort who participated in the 1999 Large Health Study of Veteran Enrollees. We analyzed data collected on HIV and HCV status, risk factors for and the incidence of CHD, and mortality from January 2000 to July 2007. We compared models to assess CHD risk when death was treated as a censoring event and as a competing risk. During the median 7.3 years of follow-up, there were 194 CHD events and 1186 deaths. Compared with HIV-HCV- Veterans, HIV+HCV+ Veterans had a significantly higher risk of CHD regardless of whether death was adjusted for as a censoring event (adjusted hazard ratio, 2.03; 95% confidence interval, 1.28 to 3.21) or a competing risk (adjusted HR, 2.45; 95% confidence interval, 1.83 to 3.27 respectively). Compared with HIV+HCV- Veterans, HIV+HCV+ Veterans also had a significantly higher adjusted risk of CHD regardless of whether death was treated as a censored event (adjusted hazard ratio, 1.93; 95% confidence interval, 1.02 to 3.62) or a competing risk (adjusted hazard ratio, 1.46; 95% confidence interval, 1.03 to 2.07).
CONCLUSIONS: HIV+HCV+ Veterans have an increased risk of CHD compared with HIV+HCV- and HIV-HCV- Veterans.

Entities:  

Mesh:

Year:  2011        PMID: 21712519      PMCID: PMC3159506          DOI: 10.1161/CIRCOUTCOMES.110.957415

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  26 in total

1.  Hepatitis C virus and atherosclerosis in patients with type 2 diabetes.

Authors:  Michiaki Fukui; Yoshihiro Kitagawa; Naoto Nakamura; Toshikazu Yoshikawa
Journal:  JAMA       Date:  2003-03-12       Impact factor: 56.272

2.  Evidence for association between hepatitis C virus seropositivity and coronary artery disease.

Authors:  C Vassalle; S Masini; F Bianchi; G C Zucchelli
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

3.  Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study.

Authors:  D G Ives; A L Fitzpatrick; D E Bild; B M Psaty; L H Kuller; P M Crowley; R G Cruise; S Theroux
Journal:  Ann Epidemiol       Date:  1995-07       Impact factor: 3.797

4.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

5.  Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.

Authors:  S H Mehta; F L Brancati; M S Sulkowski; S A Strathdee; M Szklo; D L Thomas
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

6.  Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients.

Authors:  R Bedimo; A O Westfall; M Mugavero; H Drechsler; N Khanna; M Saag
Journal:  HIV Med       Date:  2010-02-15       Impact factor: 3.180

7.  Hepatitis C virus seropositivity, but not hepatitis B virus carrier or seropositivity, associated with increased pulse wave velocity.

Authors:  Hirofumi Tomiyama; Tomio Arai; Ken-ichi Hirose; Sabroh Hori; Yoshio Yamamoto; Akira Yamashina
Journal:  Atherosclerosis       Date:  2003-02       Impact factor: 5.162

8.  Coronary heart disease in HIV-infected individuals.

Authors:  Judith S Currier; Anne Taylor; Felicity Boyd; Christopher M Dezii; Hugh Kawabata; Beth Burtcel; Jen-Fue Maa; Sally Hodder
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-01       Impact factor: 3.731

9.  Hepatitis B and C virus infection and the risk of atherosclerosis in a general population.

Authors:  Henry Völzke; Christian Schwahn; Birger Wolff; Renate Mentel; Daniel M Robinson; Volker Kleine; Stephan B Felix; Ulrich John
Journal:  Atherosclerosis       Date:  2004-05       Impact factor: 5.162

10.  Association between hepatitis C virus core protein and carotid atherosclerosis.

Authors:  Yuko Ishizaka; Nobukazu Ishizaka; Eiko Takahashi; Tadao Unuma; Ei-ichi Tooda; Hideki Hashimoto; Ryozo Nagai; Minoru Yamakado
Journal:  Circ J       Date:  2003-01       Impact factor: 2.993

View more
  56 in total

1.  Association of HIV, hepatitis C virus and liver fibrosis severity with interleukin-6 and C-reactive protein levels.

Authors:  Shailja Shah; Yifei Ma; Rebecca Scherzer; Greg Huhn; Audrey L French; Michael Plankey; Marion G Peters; Carl Grunfeld; Phyllis C Tien
Journal:  AIDS       Date:  2015-07-17       Impact factor: 4.177

2.  Decreased Lung Function and All-Cause Mortality in HIV-infected Individuals.

Authors:  Matthew R Gingo; Mehdi Nouraie; Cathy J Kessinger; Ruth M Greenblatt; Laurence Huang; Eric C Kleerup; Lawrence Kingsley; Deborah K McMahon; Alison Morris
Journal:  Ann Am Thorac Soc       Date:  2018-02

3.  Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men.

Authors:  Anne K Monroe; Wei Fu; Michelle N Zikusoka; Lisa P Jacobson; Mallory D Witt; Frank J Palella; Lawrence A Kingsley; Wendy S Post; Todd T Brown
Journal:  AIDS Res Hum Retroviruses       Date:  2015-03-09       Impact factor: 2.205

Review 4.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 5.  Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.

Authors:  Denise C Hsu; Irini Sereti
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 6.  Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer.

Authors:  John Charles A Lacson; Revery P Barnes; Hossein Bahrami
Journal:  Curr Atheroscler Rep       Date:  2017-04       Impact factor: 5.113

7.  Insomnia as an Independent Predictor of Incident Cardiovascular Disease in HIV: Data From the Veterans Aging Cohort Study.

Authors:  Brittanny M Polanka; Suman Kundu; Kaku A So-Armah; Matthew S Freiberg; Samir K Gupta; Roger J Bedimo; Matthew J Budoff; Adeel A Butt; Chung-Chou H Chang; Stephen S Gottlieb; Vincent C Marconi; Julie A Womack; Jesse C Stewart
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

8.  Short communication: risk of elevated total cholesterol/high-density lipoprotein cholesterol ratio after antiretroviral therapy in HIV/hepatitis C virus patients.

Authors:  Lisa Kakinami; Michael J Adams; Robert C Block; Susan E Cohn; Benedict Maliakkal; Susan G Fisher
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-10       Impact factor: 2.205

9.  Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV.

Authors:  William C Becker; Kirsha Gordon; E Jennifer Edelman; Robert D Kerns; Stephen Crystal; James D Dziura; Lynn E Fiellin; Adam J Gordon; Joseph L Goulet; Amy C Justice; David A Fiellin
Journal:  AIDS Behav       Date:  2016-03

10.  HIV infection and the risk of acute myocardial infarction.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice
Journal:  JAMA Intern Med       Date:  2013-04-22       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.